Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System™

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 57, Issue 5, 2002, Pages 423-430

  Moverare R ^a,b   Elfman, L ^a,b   Vesterinen, E ^c   Metso, T ^c   Haahtela, T ^c  

^a UPPSALA UNIVERSITY   (Sweden)

^b Thermo Fisher Scientific   (United States)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Bet v 1; Bet v 2; Bet v 4; IgE; Immunotherapy

Indexed keywords

ALUTARD; AQUAGEN; IMMUNOGLOBULIN E; POLLEN EXTRACT; RECOMBINANT BET V 1; RECOMBINANT BET V 2; RECOMBINANT BET V 4; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTIBODY SPECIFICITY; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC KIT; DIAGNOSTIC TEST; FEMALE; HUMAN; IMMUNOBLOTTING; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOREACTIVITY; IMMUNOTHERAPY; MALE; POLLEN ALLERGY; PRIORITY JOURNAL; SENSITIZATION;

ADOLESCENT; ADULT; ALLERGENS; ANTIBODY SPECIFICITY; BETULA; CHILD; CHILD WELFARE; CONTRACTILE PROTEINS; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOBLOTTING; IMMUNOGLOBULIN E; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; PLANT EXTRACTS; POLLEN; PROFILINS; RECOMBINANT PROTEINS; RHINITIS, ALLERGIC, SEASONAL;

EID: 0036240589     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1398-9995.2002.13248.x     Document Type: Article

References (42)

1. Allergen immunotherapy - Therapeutic vaccines for allergic diseases
2. Long-term clinical efficacy of grass-pollen immunotherapy
3. A controlled trial of immunotherapy for asthma in allergic children
4. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures
5. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals
6. Role of interleukin 10 in specific immunotherapy
7. Lymphocyte transformation by grass pollen allergens. A study of atopic patients receiving immunotherapy
8. Grass immunotherapy induces inhibition of allergen-specific human peripheral blood mononuclear cell proliferation
9. IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy
10. Immunotherapy to deciduous tree pollens: Specific IgE and IgG antibody patterns
11. Clinical and immunological effects of immunotherapy with alum-absorbed grass allergoid in grass-pollen-induced hay fever
12. Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple-pollen species. II. Efficacy of a double-blind, placebo-controlled, specific immunotherapy with standardized extracts
13. Allergen-specific increase in interleukin (IL)-4 and IL-5 secretion from peripheral blood mononuclear cells during birch-pollen immunotherapy
14. The kinetics of change in cytokine production by CD4 T cells during conventional allergen immunotherapy
15. Changes in cytokine production in vitro during the early phase of birch-pollen immunotherapy
16. Demonstration of reagin of a new specificity in sera of treated ragweed-sensitive persons
17. Evaluation of immunotherapy-induced changes in specific IgE, IgG and IgG subclasses in birch pollen allergic patients by means of immunoblotting. Correlation with clinical response
18. Specific IgE antibodies to vespids in the course of immunotherapy with Vespula germanica administered to patients sensitized to Polistes dominulus
19. The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT)
20. IgE and IgG antibodies of patients with allergy to birch pollen as tools to define the allergen profile of Betula verrucosa
21. Profilins constitute a novel family of functional plant pan-allergens
22. Molecular characterization, expression in Escherichia coli, and epitope analysis of a two EF-hand calcium-binding birch pollen allergen, Bet v 4
23. Pollen-specific rush immunotherapy: Clinical efficacy and effects on antibody concentrations
24. Molecular weight determination of protein-dodecyl sulfate complexes by gel electrophoresis in a discontinuous buffer system
25. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications
26. Purification and characterization of recombinant Bet v 1 the major birch pollen allergen. Immunological equivalence to natural Bet v 1
27. Recombinant allergens for immunoblot diagnosis of tree-pollen allergy
28. Skin testing with recombinant allergens rBet v 1 and birch profilin, rBet v 2: Diagnostic value for birch pollen and associated allergies
29. Immunological and biological properties of Bet v 4, a novel birch pollen allergen with two EF-hand calcium-binding domains
30. Comparison of recombinant timothy grass pollen allergens with natural extract for diagnosis of grass pollen allergy in different populations
31. Different profiles in specific IgE to rBet v 1 and rBet v 2 in patients allergic to birch pollen from six countries
32. Pollen-related allergy to peach and apple: An important role for profilin
33. Identification of allergens in fruits and vegetables: IgE cross-reactivities with the important birch pollen allergens Bet v 1 and Bet v 2 (birch profilin)
34. Type 1 allergic reactions to plant-derived food: A consequence of primary sensitization to pollen allergens
35. Evaluation of recombinant allergens Bet v 1 and Bet v 2 (profilin) by Pharmacia CAP system in patients with pollen-related allergy to birch and apple
36. Phenylcoumaran benzylic ether and isoflavonoid reductases are a new class of cross-reactive allergens in birch pollen, fruits and vegetables
37. Purification and characterization of an 18-kD allergen of birch (Betula verrucosa) pollen: Identification as a cyclophilin
38. 2+
39. Development of T-cell memory against inhalant allergens: Risks for the future
40. Possible induction of food allergy during mite immunotherapy
41. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study
42. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children